Myeloma Canada Board of Directors
Myeloma Canada is governed by a Board of Directors whose role is to provide leadership, guide the strategic direction of the organization, and ensure that it achieves its mission. Central to this, is the reinforcement and development of our four pillars: Education, Awareness, Access & Advocacy, and Science & Research.
Johanne Mullen, Chair
Johanne Mullen is a partner in the Deals Practice of PricewaterhouseCoopers LLP. She specializes in project financing and public-private partnerships (PPPs), and provides advice to clients with respect to the development and financing of large projects, notably in the infrastructure sector. Her advisory experience includes developing business cases, developing financing and funding strategies, securing credit ratings, running competitions to identify financiers, as well as implementing, negotiating, and closing financings.
Some of Johanne’s recent mandates include McGill University Health Centre’s $1.3 billion redeployment to the Glen campus; Centre hospitalier universitaire de Québec’s redevelopment of the Hôtel Dieu Hospital; the cities of Longueuil and Montreal water infrastructure funding; and city of Montreal’s transportation infrastructure funding.
Johanne is regularly invited to speak at conferences on the subjects of PPPs and project financing. She is also president of the “Institut pour le partenariat public privé du Québec” (Institute for public private partnerships of Quebec).
Johanne holds a Bachelor of Commerce in Finance from Concordia University and a Master of Business Administration in International Business from McGill University.
Eric Low, Vice-Chair
Eric Low has worked in the field of medical research charities for over 20 years. He founded Myeloma UK in 1996 and was their Chief Executive until February 2017. Currently, Eric combines working for the Amyloidosis Research Consortium as their Head of Global Strategy with a consultancy business specialising primarily in evidence development, stakeholder engagement and market access strategies.
Eric describes himself as incredibly committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His career goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of rare diseases.
Central to achieving this, Eric has a strong track record of delivery and success in building multi-stakeholder research collaborations and consortia, and delivering innovative solutions to complex issues, challenges and barriers standing in the way of progress.
Eric also holds several board, honorary, advisory and voluntary positions and advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.
Ellis Basevitz, Treasurer
Ellis Basevitz joined Myeloma Canada’s Board of Directors, as treasurer. He is the founder of the accounting firm PSB Boisjoli.
Ellis owes his career success to his ability to establish lasting relationships with clients and business partners. Known for his enthusiasm for problem solving, he provides original and creative ideas that help clients save money and grow their assets. His services are based on mutual trust, knowing how to listen to and understand the needs and objectives of clients, and partnering with clients in the development of short and long-term strategies, whether personal or business.
During his career, Ellis has been a mentor and an example for many young accountants who have now become partners. He has shared with them his philosophy on customer service and trained them to provide value-added services.
Within the firm, Ellis is a consultant valued for his vision, creativity, and originality, and has assumed marketing and business development roles.
Ellis is a Quebec Chartered Accountant (CA). He is also a member of the Ordre des comptables agréés du Québec and of the Canadian Institute of Chartered Accountants.
Donna Reece, MD, Director
Donna Reece is Professor of Medicine at the University of Toronto and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. She holds the Molly and David Bloom Chair in Multiple Myeloma Research and is Chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, as well as a Co-Chair of the Myeloma Working Committee at the Center for International Blood and Marrow Transplant Research. She also serves on the Myeloma Canada Scientific Advisory Board and leads the Myeloma Canada Research Network.
Anthony Reiman, MD, Director
Anthony Reiman is a medical oncologist with a special interest in the study and treatment of myeloma. He is based at the Saint John Regional Hospital in New Brunswick and is a member of the Board of Directors of the New Brunswick Health Research Foundation and of the Beatrice Hunter Cancer Research Institute. He is the Canadian Cancer Society Research Chair at the University of New Brunswick and the Assistant Dean, Research, at Dalhousie Medicine, New Brunswick.
Anthony is currently a Professor of Medicine at Dalhousie University, and is an active researcher with over 100 publications in peer-reviewed journals. Anthony is also the co-chair of the myeloma committee at the Canadian Cancer Trials Group, and a member of both the US National Cancer Institute Myeloma Steering Committee and the International Myeloma Working Group. He sits on several committees with the Myeloma Canada Research Network.
Anthony Everett, Director
Anthony Everett is a passionate philanthropist who excels at articulating compelling visions for success and promotes value-based relationships with internal and external stakeholders.
In 2011, Anthony was appointed by the City of Prince George to lead northern British Columbia as the head volunteer and board chair of the Host Society for the 2015 Canada Winter Games. In this position, Anthony helped the Host Society to successfully produce and execute the largest multi-sport and cultural event in northern BC history. Additionally, his strategic oversight helped build positive relationships with all levels of government and generated $8 million in private sector funding to enhance the 2015 Canada Winter Games’ business plan, and to enhance sport and cultural experiences.
As a visionary for innovative strategies and successful leadership, Anthony created a nationally recognized, award-winning staff team for the Northern British Columbia Tourism Association (NBCTA), in the areas of tourism marketing, destination branding, and community tourism development. In the role of CEO for NBCTA, he designed and implemented a new approach to re-establish trust with northern BC communities and tourism operator. The new approach included introducing principles of value-based leadership, collaborative tourism development, and supportive business initiatives. Over the course of nine years with NBCTA, Anthony raised the profile of the northern BC tourism sector regionally, provincially, and nationally.
Anthony now works as a consultant. He provides strategic planning assistance, meeting facilitation, and community tourism planning, including marketing and communication planning as well as guidance to board directors through governance workshops. He is also engaged as a passionate public speaker on the subjects of leadership, sport, tourism, and health.
Aldo Del Col, Late Co-founder and Special Advisor to Chair until August 5, 2019
It is with profound sadness that we have learned of the passing of Aldo Del Col, M.S.M., our Co-founder, dear friend and mentor on August 6, 2019 due to unforeseen complications related to multiple myeloma. Aldo leaves behind an incredible legacy of passion, determination and accomplishments.
Since being diagnosed with multiple myeloma in 2002, Aldo Del Col directed his attention to creating an effective national platform to address the needs of the Canadian myeloma community. In 2004 he founded the Myeloma Montreal Support Network, and in 2005 he co-founded Myeloma Canada. Aldo focused his efforts on establishing the organization as the voice of the Canadian myeloma community, first as President of the Board of Directors, then as Executive Director from 2010 to 2013, and as Chairman of the Board until 2018. More recently he co-founded the Myeloma Canada Research Network (MCRN), a sister organization to Myeloma Canada, to accelerate the advancement of Canadian myeloma research. Drawing upon his scientific and pharmaceutical background, he worked closely with Canada’s leading myeloma researchers, investigators, clinicians, and pharmaceutical companies to drive research toward finding a cure and improving patient outcomes.
Aldo held a Bachelor of Science in Pharmacy degree from the University of Toronto and a Master in Business Administration from York University. Throughout his extensive career, Aldo gained knowledge and experience not only as a Community Pharmacist, but also as a Financial Analyst for a multinational pharmaceutical company and National Director of Sales and Marketing for a global health and beauty consumer products corporation.
In addition to his ongoing responsibilities with Myeloma Canada and the Myeloma Canada Research Network, Aldo continued to work part time in a community pharmacy, and served as the hematology patient representative for the Canadian Cancer Trials Group (CCTG) and as a reviewer for their Clinical Trials Committee. He was also a member of the Global Myeloma Action Network (GMAN), served on the Board of Directors of the International Myeloma Foundation (IMF), and participated in both national and international advisory boards.